WTA Introduces Mandatory Genetic Sex Testing for Players

New Rules Take Effect

The WTA will require every player wishing to compete on its tour to undergo a one‑time genetic test beginning Tuesday. The test can be completed with a cheek swab, a blood sample, or a saliva collection. If the SRY gene—associated with male characteristics—is detected, the athlete will face an additional medical assessment before being cleared to play. Players who refuse testing must sign a document acknowledging they could be subject to disciplinary action.

How the Test Works

The examination looks for the presence of the SRY gene, a marker on the Y chromosome that signals male biological traits. A positive result triggers a further medical evaluation to determine eligibility. Previously, the WTA’s eligibility policy allowed transgender women to compete after declaring a female gender identity and maintaining testosterone below 2.5 nmol/L for two years. After a recent review and consultation with its members, the board approved a new policy that will be applied starting in 2026, based purely on biological sex. The organization stressed that while the policy draws a clear line between biological females and males, it does not aim to disrespect any individual’s gender identity or dignity.

Precedent Across Other Sports

The WTA’s move follows similar steps taken by other major governing bodies. World Athletics implemented a one‑off genetic test for female competitors last September. World Boxing made the SRY test compulsory for female athletes in May of the previous year. The International Olympic Committee also announced plans to adopt the same approach ahead of the 2028 Los Angeles Games. These coordinated actions indicate a growing trend toward biological definitions in elite women’s competition.

What It Means for Players

There are currently no known transgender women playing on the WTA Tour or at any professional tennis level. The new rule establishes a clear biological benchmark that will shape future eligibility after 2026. Competitors must accept the single genetic test and any subsequent medical review if they test positive. By shifting to a biology‑based standard, the WTA aims to protect fair competition while navigating a highly sensitive issue. The governing body reiterated that the policy is not intended to question or diminish the dignity of any individual’s gender identity.